ONCY - Oncolytics Biotech GAAP EPS of -$0.09 misses by $0.01
- Oncolytics Biotech press release ( NASDAQ: ONCY ): Q2 GAAP EPS of -$0.09 misses by $0.01 .
- $33.7M in cash and cash equivalents provides projected runway into the second half of 2023 and through key clinical readouts in breast and pancreatic cancer.
For further details see:
Oncolytics Biotech GAAP EPS of -$0.09 misses by $0.01